Skip to main content
Clinical Trials/NCT03107520
NCT03107520
Recruiting
Early Phase 1

Use of Intraoperative Contrast-enhanced Ultrasound to Evaluate Femoral Head Perfusion in Infants With Developmental Dysplasia of the Hip at the Time of Surgical Reduction

Children's Hospital of Philadelphia1 site in 1 country125 target enrollmentMay 22, 2017

Overview

Phase
Early Phase 1
Intervention
Intraoperative contrast-enhanced ultrasound (CEUS)
Conditions
Developmental Dysplasia of the Hip
Sponsor
Children's Hospital of Philadelphia
Enrollment
125
Locations
1
Primary Endpoint
Visualization of epiphyseal vascularity in the femoral head
Status
Recruiting
Last Updated
17 days ago

Overview

Brief Summary

This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.

Detailed Description

For children presenting with late-diagnosed developmental dysplasia of the hip, a closed or open hip reduction followed by hip spica casting may be indicated if conservative treatment fails. Although closed or open reduction and casting is largely successful for relocating a hip, iatrogenic avascular necrosis remains a major source of morbidity as a result of the surgical procedure. Although recent evidence has demonstrated that postoperative gadolinium-enhanced magnetic resonance (MR) studies may be useful in assessing perfusion of the hip after surgery, these studies are not performed until after the cast is placed and they do not elucidate the specific intraoperative steps that increase risk for osteonecrosis. Contrast-enhanced ultrasound (CEUS) may be a reliable and effective alternative.

Registry
clinicaltrials.gov
Start Date
May 22, 2017
End Date
April 1, 2030
Last Updated
17 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males or females between 4 months and up to and including 24 months of age at the time of surgery.
  • Diagnosed with DDH.
  • Failed conservative treatment, or present with late-diagnosed DDH (where conservative treatment would not be appropriate to initiate at their age), and are undergoing closed or open reduction and spica casting.
  • Informed consent (parental permission)

Exclusion Criteria

  • \> 24 months of age at the time of surgery.
  • Subjects with DDH who are successfully treated with conservative measures and do not require surgical reduction.
  • Previous open hip reduction of the affected side
  • Children with known complex congenital heart disease or unstable cardiopulmonary conditions (as noted in the package labeling for Lumason) including acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure or serious ventricular arrhythmias will be excluded.
  • History of allergic reaction to Lumason, sulfur hexafluoride, sulfur hexafluoride lipid microsphere components, or other ingredients in Lumason (polyethylene glycol, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Ns), palmitic acid).Parental/guardian permission (informed consent) and if appropriate, child assent.

Arms & Interventions

DDH Surgical Reduction Patients

Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.

Intervention: Intraoperative contrast-enhanced ultrasound (CEUS)

DDH Surgical Reduction Patients

Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.

Intervention: Lumason

Outcomes

Primary Outcomes

Visualization of epiphyseal vascularity in the femoral head

Time Frame: 1 day

The visualization of epiphyseal vascularity on the sonogram from intraoperative CEUS will be assessed by a trained sonographer and musculoskeletal radiologist administering the CEUS and reviewing the images.

Secondary Outcomes

  • Estimate and predict the likelihood of developing avascular necrosis(Approximately 3 years)
  • Comparison of CEUS and Post-Operative Imaging(Approximately 3 years)

Study Sites (1)

Loading locations...

Similar Trials